Kidiaven Nouveau-Ne 1 (Valine, Acetylcysteine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine)

Kidiaven Nouveau‑Ne 1 is used in parenteral nutrition to provide amino acids for patients with inadequate oral intake.

• Parenteral nutrition for infants and children: Supplies a balanced mix of essential and non‑essential amino acids to meet growth and metabolic demands.
• Support of protein synthesis in patients unable to meet nutritional needs orally: Enhances nitrogen balance and promotes tissue repair.
• Preterm neonates requiring amino acid supplementation: Provides critical substrates for rapid growth and organ development.

• The solution delivers a mixture of essential and non‑essential amino acids directly into the bloodstream, bypassing the gastrointestinal tract. These amino acids serve as substrates for ribosomal protein synthesis, replenish nitrogen stores, and support metabolic pathways such as gluconeogenesis and neurotransmitter production, thereby maintaining nitrogen balance and facilitating tissue growth in patients who cannot ingest adequate protein orally.

Kidiaven Nouveau‑Ne 1 may be associated with the following adverse reactions.

Common Side Effects

• Infusion site erythema or pain: mild local irritation at the catheter site.
• Nausea or vomiting: transient gastrointestinal discomfort.
• Transient metabolic alkalosis: mild shift in acid‑base balance.
• Hyperglycemia: elevation of blood glucose levels, especially in diabetic patients.
• Electrolyte disturbances (e.g., mild hypernatremia): changes in serum electrolytes.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rapid onset of hypotension, bronchospasm, or urticaria.
• Hyperosmolarity leading to renal dysfunction: impaired kidney function due to high solute load.
• Metabolic acidosis: significant acid‑base imbalance requiring intervention.
• Thrombophlebitis: inflammation and clot formation in the vein.
• Sepsis related to catheter infection: systemic infection originating from the infusion line.

When using Kidiaven Nouveau‑Ne 1, clinicians should observe the following precautions.

• Assess renal function: adjust infusion rate in patients with impaired kidney function.
• Monitor electrolytes: regular checks of serum sodium, potassium, and calcium levels.
• Evaluate acid‑base status: watch for metabolic alkalosis or acidosis during therapy.
• Use aseptic technique: prevent catheter‑related infections.
• Adjust for hepatic impairment: consider reduced metabolism of certain amino acids.
• Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake.

Kidiaven Nouveau‑Ne 1 can interact with other agents administered concurrently.

Major Interactions (Avoid)

• High‑dose glucocorticoids: may increase protein catabolism, reducing efficacy.
• Loop diuretics: can exacerbate electrolyte imbalances, especially potassium loss.

Moderate Interactions (Monitor Closely)

• Insulin therapy: amino acids may affect glucose control, requiring dose adjustment.
• Other parenteral nutrition components: risk of incompatibility or precipitation.
• Anticoagulants (heparin): may increase risk of bleeding at infusion site.
• Mineral supplements (e.g., calcium, phosphate): monitor for precipitation in the solution.